Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Igc Pharma Inc (IGC)

Igc Pharma Inc (IGC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,186
  • Shares Outstanding, K 98,796
  • Annual Sales, $ 1,270 K
  • Annual Income, $ -7,120 K
  • EBIT $ -8 M
  • EBITDA $ -7 M
  • 60-Month Beta 0.30
  • Price/Sales 24.24
  • Price/Cash Flow N/A
  • Price/Book 3.68
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.07
  • Most Recent Earnings $-0.02 on 11/14/25
  • Next Earnings Date 06/26/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 310.06% (+21.70%)
  • Historical Volatility 51.29%
  • IV Percentile 34%
  • IV Rank 21.20%
  • IV High 939.31% on 03/17/26
  • IV Low 140.73% on 08/18/25
  • Expected Move (DTE 27) 0.0425 (12.65%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 43
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 5,523
  • Open Int (30-Day) 4,908
  • Expected Range 0.2934 to 0.3784

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.02
  • Number of Estimates 1
  • High Estimate $-0.02
  • Low Estimate $-0.02
  • Prior Year $-0.01
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2500 +34.36%
on 03/25/26
0.3359 unch
on 04/17/26
+0.0469 (+16.23%)
since 03/17/26
3-Month
0.2420 +38.80%
on 02/09/26
0.3359 unch
on 04/17/26
+0.0396 (+13.36%)
since 01/16/26
52-Week
0.2420 +38.80%
on 02/09/26
0.4985 -32.62%
on 08/27/25
+0.0522 (+18.40%)
since 04/17/25

Most Recent Stories

More News
New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Vivos Therapeutics

The show also broadcasts as sponsored programming additionally across MENA and Latin America as "Nuevo En La Calle," reaching millions of households worldwide weekly, with expanded digital distribution...

CAST : 3.51 (-8.59%)
NTHI : 5.34 (+6.37%)
ACXP : 2.38 (-4.42%)
IGC : 0.3359 (+4.64%)
VTIX : 6.17 (+1.31%)
MDCX : 0.3513 (+16.98%)
YYGH : 1.6100 (+5.92%)
DVLT : 0.7580 (-9.49%)
VVOS : 0.9741 (-10.63%)
New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX)

The show also broadcasts across MENA and Latin America as sponsored programming.

TRN : 32.95 (+1.48%)
PETV : 0.7990 (unch)
SNYR : 0.5246 (+3.49%)
ACXP : 2.38 (-4.42%)
IGC : 0.3359 (+4.64%)
VTIX : 6.17 (+1.31%)
LTRN : 2.49 (-1.97%)
NRXP : 2.55 (+1.59%)
YYGH : 1.6100 (+5.92%)
DVLT : 0.7580 (-9.49%)
VVOS : 0.9741 (-10.63%)
New to The Street and IGC Pharma (NYSE American:IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning

NEW YORK, NY / ACCESS Newswire / March 25, 2026 / New to The Street, a premier financial media platform known for its national television distribution and integrated investor engagement strategy, today...

IGC : 0.3359 (+4.64%)
IGC Pharma Subsidiary Signs Asset Sale Agreement

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. IGC Pharma...

IGC : 0.3359 (+4.64%)
IGC Pharma Welcomes Strategic Investment from Advisors

POTOMAC, MARYLAND / ACCESS Newswire / April 24, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that the Company's recently appointed advisors entered into a Share...

IGC : 0.3359 (+4.64%)
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

Industry Veterans Bring Deep Strategic Experience to Guide Alzheimer's Clinical Expansion and Commercial Strategy

IGC : 0.3359 (+4.64%)
IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

POTOMAC, MARYLAND / ACCESS Newswire / April 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the expansion of its ongoing Phase 2 CALMA clinical trial with...

IGC : 0.3359 (+4.64%)
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

POTOMAC, MARYLAND / ACCESS Newswire / April 1, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its Phase 2 clinical trial, CALMA, evaluating IGC-AD1 for the treatment of agitation...

IGC : 0.3359 (+4.64%)
IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

- IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer's -

IGC : 0.3359 (+4.64%)
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

POTOMAC, MD / ACCESS Newswire / March 20, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 CALMA trial for IGC-AD1 with the addition...

IGC : 0.3359 (+4.64%)

Business Summary

IGC Pharma Inc. develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. IGC Pharma Inc., formerly known as India Globalization Capital Inc., is based in POTOMAC, Md....

See More

Key Turning Points

3rd Resistance Point 0.3558
2nd Resistance Point 0.3458
1st Resistance Point 0.3409
Last Price 0.3359
1st Support Level 0.3260
2nd Support Level 0.3160
3rd Support Level 0.3111

See More

52-Week High 0.4985
Fibonacci 61.8% 0.4005
Fibonacci 50% 0.3702
Fibonacci 38.2% 0.3400
Last Price 0.3359
52-Week Low 0.2420

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.